An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) CEO to Speak at Noble Capital Markets Healthcare Conference. Atossa is a clinical stage biopharmaceutical company focusing on breast cancer treatments.
Positive
None.
Negative
None.
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.
Contact Eric Van Zanten VP, Investor and Public Relations 610-529-6219 eric.vanzanten@atossainc.com
FAQ
When will the Atossa CEO speak at the Noble Capital Markets Healthcare Conference?
The Atossa CEO, Steven Quay, will speak on Wednesday, April 17 at 9:00 am ET.
What is the focus of Atossa Therapeutics?
Atossa is focusing on developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Where can individuals register to view the live presentation?
Individuals can register for the free event at Noble Healthcare Conference Registration.
Where can a video replay of the presentation be viewed?
A video replay will be available for 90 days on Atossa's investor relations page: https://investors.atossatherapeutics.com and on Channelchek: www.channelchek.com.
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.